Travere therapeutics announces european commission has granted orphan designation to sparsentan for the treatment of iga nephropathy

San diego, feb. 18, 2021 (globe newswire) -- travere therapeutics, inc. (nasdaq: tvtx) today announced the european commission (ec) has granted orphan designation to sparsentan for the treatment of iga nephropathy (igan), a rare kidney disorder and a leading cause of end-stage kidney disease (eskd). sparsentan is an investigational product candidate currently being evaluated in a pivotal phase 3 clinical study for the treatment of igan, as well as a pivotal phase 3 clinical study for the treatment of focal segmental glomerulosclerosis (fsgs). the company recently reported that the ongoing duplex study of sparsentan in fsgs achieved its pre-specified interim proteinuria endpoint and that preliminary results from the interim analysis suggest that to date in the study, sparsentan has been generally well-tolerated and has shown a comparable safety profile to irbesartan. topline data from the interim proteinuria assessment in the ongoing protect study of sparsentan in igan remain on track to be reported in the third quarter of 2021.
TVTX Ratings Summary
TVTX Quant Ranking